David Allan - Avivagen Director
| VIV Stock | CAD 0.01 0.00 0.00% |
Director
Mr. David G. P. Allan is Director of the Company. Allan has considerable experience in life sciences, capital markets and corporate governance. He was the founding chairman, and chief executive officer from 1998 to 2010, of the U.S. and Canadianlisted oncology therapeutics development company YM BioSciences Inc. until its acquisition by Gilead Sciences Inc. for 510million in 2013, the founding chairman of AvidBiologics, the executive chairman of Stem Cell Therapeutics Corporationration and lead director of DiaMedica Inc. until 2013. He was a chief executive officer or senior executive of three independent Canadian investment dealers and a governor of the Toronto Stock Exchange. He was a member of the Awards Selection Committee of the Canadian Networks of Centers of Excellence and the Canada Foundation for Innovation multidisciplinary assessment committee and was the recipient of the Gold Leaf Award from BIOTECanada for Industry Leadership in 2012. since 2015.
| Tenure | 9 years |
| Address | 100 Sussex Drive, Ottawa, ON, Canada, K1A 0R6 |
| Phone | 613-702-2908 |
| Web | https://www.avivagen.com |
Avivagen Management Efficiency
The company has return on total asset (ROA) of (1.9344) % which means that it has lost $1.9344 on every $100 spent on assets. This is way below average. Avivagen's management efficiency ratios could be used to measure how well Avivagen manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 2.28 in 2024, whereas Return On Tangible Assets are likely to drop (4.20) in 2024. At this time, Avivagen's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 148.9 K in 2024, whereas Intangible Assets are likely to drop 347.99 in 2024.Similar Executives
| Found 4 records | DIRECTOR Age | ||
| Sarah Prichard | Kane Biotech | N/A | |
| Mark Nawacki | Kane Biotech | N/A | |
| Arvind Joshi | Kane Biotech | N/A | |
| Rashieda Gluck | Kane Biotech | N/A | |
Management Performance
| Return On Asset | -1.93 |
Avivagen Leadership Team
Elected by the shareholders, the Avivagen's board of directors comprises two types of representatives: Avivagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avivagen. The board's role is to monitor Avivagen's management team and ensure that shareholders' interests are well served. Avivagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avivagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tracy BVSC, Director Manager | ||
| David Hankinson, Executive Director | ||
| Louis Hui, Director - Business Development | ||
| Chris Boland, CFO | ||
| David Allan, Director | ||
| Ira Levy, Interim Officer | ||
| Amin Khalifa, Independent Director | ||
| Aubrey Dan, Director | ||
| Cameron Groome, CEO and President and Director | ||
| Vanessa Grant, Director | ||
| Andrew Basek, Director of Investor Relations | ||
| Drew Basek, Director of Investor Relations | ||
| Paul Mesburis, Lead Director | ||
| James Nickerson, President Innovation | ||
| Graham Burton, Co-Founder, Director of Commercialization Science and Director | ||
| G Anthony, Independent Director |
Avivagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avivagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.93 | ||||
| Operating Margin | (10.47) % | ||||
| Current Valuation | 7.61 M | ||||
| Shares Outstanding | 77.69 M | ||||
| Shares Owned By Insiders | 1.11 % | ||||
| Number Of Shares Shorted | 6.25 K | ||||
| Price To Earning | (7.32) X | ||||
| Price To Sales | 0.54 X | ||||
| Revenue | 939.17 K | ||||
| Gross Profit | 400.3 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Avivagen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Avivagen's short interest history, or implied volatility extrapolated from Avivagen options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Avivagen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Avivagen Stock analysis
When running Avivagen's price analysis, check to measure Avivagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avivagen is operating at the current time. Most of Avivagen's value examination focuses on studying past and present price action to predict the probability of Avivagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avivagen's price. Additionally, you may evaluate how the addition of Avivagen to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |